RYVU THERAPEUTICS ZY-40
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It… Read more
Market Cap & Net Worth: RYVU THERAPEUTICS ZY-40 (9Y4)
RYVU THERAPEUTICS ZY-40 (F:9Y4) has a market capitalization of $129.34 Million (€126.00 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #18225 globally and #1910 in its home market, demonstrating a -3.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RYVU THERAPEUTICS ZY-40's stock price €5.45 by its total outstanding shares 23119465 (23.12 Million).
RYVU THERAPEUTICS ZY-40 Market Cap History: 2021 to 2026
RYVU THERAPEUTICS ZY-40's market capitalization history from 2021 to 2026. Data shows change from $311.83 Million to $129.34 Million (-12.69% CAGR).
RYVU THERAPEUTICS ZY-40 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RYVU THERAPEUTICS ZY-40's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9Y4 by Market Capitalization
Companies near RYVU THERAPEUTICS ZY-40 in the global market cap rankings as of March 19, 2026.
Key companies related to RYVU THERAPEUTICS ZY-40 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
RYVU THERAPEUTICS ZY-40 Historical Marketcap From 2021 to 2026
Between 2021 and today, RYVU THERAPEUTICS ZY-40's market cap moved from $311.83 Million to $ 129.34 Million, with a yearly change of -12.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €129.34 Million | -11.95% |
| 2025 | €146.90 Million | -29.74% |
| 2024 | €209.07 Million | -34.64% |
| 2023 | €319.90 Million | +29.87% |
| 2022 | €246.33 Million | -21.00% |
| 2021 | €311.83 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of RYVU THERAPEUTICS ZY-40 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $129.34 Million USD |
| MoneyControl | $129.34 Million USD |
| MarketWatch | $129.34 Million USD |
| marketcap.company | $129.34 Million USD |
| Reuters | $129.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.